

參考文獻

1. Markham KR. Flavones, flavonols and their glycosides. *Methods in Plant Biochemistry*. 1989 ; 1 : 197-235.
2. Hertog MG. Kromhout D., Aravanis C., Blackburn H. Buzina R. Fidanza F. Giampoli S. Jansen A. Feskens EJM. Hollman PCH. Katan MB. Flavonoid intake and long-term risk of coronary heart disease and cancer in seven countries study. *Archives of Internal Medicine*. 1995 ; 155 : 381-386.
3. Hertog MGL. Feskens EJM. Hollman PCH. Katan MB. Kromhout D. Dietary antioxidant flavonoids and the risk of coronary heart disease: the Zutphen Elderly Study. *Lancet*. 1993;34:1007
4. Knekt P. Jarvinen R. Reunanen A. Maatela J. Flavonoid intake and coronary mortality in Finland: a cohort study. *British Medical Journal*. 1996;312:478-81.
5. de Groot H. Rauen U. Tissue injury by reactive oxygen species and the protective effects of flavonoids. *Fundamental & Clinical Pharmacology*. 1998; 12:249-55.
6. Ness AR. Powles JW. Fruit and vegetables and cardiovascular disease: a review. *International Journal of Epidemiology*. 1997 ; 6 : 1-13.
7. Steinmetz KA. Potter JD. Vegetables, fruit, and cancer prevention: a review. *Journal of the American Dietetic Association*. 1996 ; 96 : 1027-39.
8. Middleton EJ. Effect of plant flavonoids on immune and inflammatory cell function. *Advances in Experimental Medicine and Biology*.

- 1998;439:175–82.
9. Raso GM. Meli R. Di Carlo G. Pacilio M and Di Carlo R. Inhibition of inducible nitric oxide synthase and cyclooxygenase-2 expression by flavonoids in macrophage J774A.1. *Life Science*. 68: 921-931, 2001.
 10. Lindachl M and Tagesson C, Flavonoids as phospholipase A₂ inhibitors : importance of their structure for selective inhibition of group II phospholipase A₂. *Inflammation*. 21: 347-356, 1997.
 11. Wang HK. Xia Y. Yang ZY. Natschke SL. Lee KH. Recent advances in the discovery and development of flavonoids and their analogues as antitumor and anti-HIV agents. *Advances in Experimental Medicine and Biology* 1998; 439: 191–225.
 12. Kaul TN, Middleton E Jr, Ogra PL. Antiviral effect of flavonoids on human viruses. *Journal of Medical Virology*. 1985;15:71–9.
 13. Knekt P, Jarvinen R, Seppanen R, et al. Dietary flavonoids and the risk of lung cancer and other malignant neoplasms. *American Journal of Epidemiology*. 1997;146:223–30.
 14. Fotsis T, Pepper MS, Aktas E, et al. Flavonoids, dietary-derived inhibitors of cell proliferation and in vitro angiogenesis. *Cancer Research*. 1997;57:2916–21.
 15. Hirano R. Sasamoto W. Matsumoto A. Itakura H. Igarashi O. Kondo K. Antioxidant ability of various flavonoids against DPPH radicals and LDL oxidation. *Journal of Nutritional Science and Vitaminology*. 47 (2001) 357–362.
 16. Rice-Evans CA. Miller NJ. Paganga G. Structure-antioxidant activity relationships of flavonoids and phenolic acids. *Free Radical Biology & Medicine*. 20 (1996) 933–956.

17. The merck index 第十三版
18. ChemFinder.Com database & Internet serch, <http://chemfinder.cambridgesoft.com/>
19. 中藥寶典，二仙堂中藥房，滿庭芳有限公司，pp. 3597
20. Hendriks JJ. de Vries HE. van der Pol SM. van den Berg TK. van Tol EA. Dijkstra CD. Flavonoids inhibit myelin phagocytosis by macrophages; a structure-activity relationship study. *Biochemical Pharmacology*. 65(5):877-85, 2003.
21. Taubert D. Berkels R. Klaus W. Roesen R. Nitric oxide formation and corresponding relaxation of porcine coronary arteries induced by plant phenols: essential structural features. *Journal of Cardiovascular Pharmacology*. 40(5):701-13, 2002.
22. Chen YC. Shen SC. Lee WR. Lin HY. Ko CH. Shih CM. Yang LL. Wogonin and fisetin induction of apoptosis through activation of caspase 3 cascade and alternative expression of p21 protein in hepatocellular carcinoma cells SK-HEP-1. *Archives of Toxicology*. 76(5-6):351-9, 2002.
23. Lee WR. Shen SC. Lin HY. Hou WC. Yang LL. Chen YC. Wogonin and fisetin induce apoptosis in human promyeloleukemic cells, accompanied by a decrease of reactive oxygen species, and activation of caspase 3 and Ca(2+)-dependent endonuclease. *Biochemical Pharmacology*. 63(2):225-36, 2002.
24. Fotsis T. Pepper MS. Montesano R. Aktas E. Breit S. Schweigerer L. Rasku S. Wahala K. Adlercreutz H. Phytoestrogens and inhibition of angiogenesis. [Review] [56 refs]. *Bailliere's Clinical Endocrinology*

- and Metabolism*. 12(4):649-66, 1998.
25. Ferreira AC. Lisboa PC. Oliveira KJ. Lima LP. Barros IA. Carvalho DP. Inhibition of thyroid type 1 deiodinase activity by flavonoids *Food & Chemical Toxicology*. 40(7):913-7, 2002.
 26. Hiipakka RA. Zhang HZ. Dai W. Dai Q. Liao S. Structure-activity relationships for inhibition of human 5 α -reductases by polyphenols *Biochemical Pharmacology*. 63(6):1165-76, 2002.
 27. Jousen AM. Rohrschneider K. Reichling J. Kirchhof B. Kruse FE. Treatment of corneal neovascularization with dietary isoflavonoids and flavonoids, *Experimental Eye Research*. 71(5):483-7, 2000.
 28. Cheong H. Ryu SY. Oak MH. Cheon SH. Yoo GS. Kim KM., Studies of structure activity relationship of flavonoids for the anti-allergic actions, *Archives of Pharmacal Research*. 21(4):478-80, 1998.
 29. Park JB. Flavonoids are potential inhibitors of glucose uptake in U937 cells. *Biochemical & Biophysical Research Communications*. 260 (2):568-74, 1999.
 30. Barone GW. Gurley BJ. Ketel BL. Abul-Ezz SR. Herbal supplements: a potential for drug interactions in transplant recipients. *Transplantation*. 2001;71(2):239-41.
 31. Ruschitzka F. Meier PJ. Turina M. Leuscher TF. Noll G. Acute heart transplant rejection due to St. John's wort. *Lancet*. 2000;355:548-9.
 32. Barone GW. Gurley BJ. Ketel BL. Lighfoot ML. Abul-Ezz SR. Drug interaction between St. John's wort and cyclosporine. *Annals of Pharmacotherapy* 2000;34(9):1013-6.
 33. Victor W. Armstrong, Michael Oellerich. New developments in the immunosuppressive drug monitoring of cyclosporine, tacrolimus, and

- azathioprine. *Clinical Biochemistry*. 34 (2001) 9–16.
34. Randall J. Dumontl and Mary H.H. Ensom. Methods for Clinical Monitoring of Cyclosporin in Transplant Patients. *Clinical Pharmacokinetics*. 2000 May; 38 (5): 427-447
35. Hebert MF. Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery. *Advanced Drug Delivery Reviews*. 1997 ; 27 : 201-214.
36. Janice Hunter. Barry H. Hirst. Intestinal secretion of drugs. The role of P-glycoprotein and related drug efflux systems in limiting oral drug absorption. *Advanced Drug Delivery Reviews*. 1997 ; 25 : 129-157.
37. Verschraagen M. Koks CHW. Schellens JHM. Beijnen JH. P-glycoprotein system as a determinant of drug interactions : The case of digoxin-verapamil. *Pharmacological Research: the Official Journal of the Italian Pharmacological Society*. 1999 ;40(4):301-306.
38. Hodaek P. Trefil P. and Stiborova M. 2002. Flavonoids-potent and versatile biologically active compounds interacting with cytochromes P450. *Chemico-Biological Interactions*. 139: 1-21.
39. Edwards DJ, Bernier SM. Naringin and naringenin are not the primary CYP3A inhibitors in grapefruit juice. *Life Sciences*. 1996 ; 59 : 1025-1030.
40. Chieli E. Romiti N. Cervelli F. and Tongiani R. 1995. Effects of flavonols on P-glycoprotein activity in cultured rat hepatocytes. *Life Sciences*. 57: 1741-1751.
41. Scambia G. Ranelletti FO. Panici PB, De Vincenzo R. Bonanno G. Ferrandina G. Piantelli M. Bussa S. Rumi C. Cianfriglia M. 1994.

- Quercetin potentiates the effect of adriamycin in a multidrug-resistant MCF-7 human breast-cancer cell line: P-glycoprotein as a possible target. *Cancer Chemotherapy and Pharmacology*. 34: 459-464.
42. Ferte J. Kuhnel JM. Chapuis G. Rolland Y. Lewin G. and Schwaller M.A. Flavonoid-related modulators of multidrug resistance: synthesis, pharmacological activity and structure-activity relationships. *Journal of Medicinal Chemistry*. 42 (1999) 478-489.
43. Dennis J. Cada. *Drug Facts and Comparisons*, USA. 1999 3777-3787.
44. Tohru Saeki, Kazumitsu Ueda, Yusuke Tanigawara, Ryohei Hori. and Tohru Komano. Human p-glycoprotein transports cyclosporin A and FK506. *The Journal of Biological Chemistry*. 1993 ; 268(9) : 6077-6080.
45. Paolo M. Biffignandi. Anna Rita Bilia. The growing knowledge of St. John's wort (*Hypericum perforatum* L) drug interactions and their clinical significance. *Current Therapeutic Research, Clinical and Experimental*. 2000 ; 61(7) : 389-394.
46. Gerald K. McEvoy. *AHFS Drug Information*, USA. 2000 ; 3374-3389.
47. GC Yee. TR McGurine. Pharmacokinetic drug interactions with cyclosporine. *Clinical Pharmacokinetics*. 1990 ; 19 : 319-332, 400-415.
48. Hou YC. Hisu SL. Tao CW. Wang YH. Chao PDL. Acute intoxication of Cyclosporin caused by coadministration of decoctions of the fruits

- of *Citrus aurantium* and the pericarps of *Citrus grandis*. *Planta Medica*. 2000 ; 66 : 653-655.
49. Barbara A. Randy AW. Drug interactions with grapefruit juice. *Clinical Pharmacokinetics*. 1997 ; 33(2) : 103-121.
50. Johnstone RW. Ruefli AA. Smyth MJ. Multiple physiological functions for multidrug transporter P-glycoprotein. *Trends in Biochemical Sciences*. 2000 ; 25 (1) : 1-6.
51. Ambudkar SV. Dey S. Hrycyna CA. Ramachandra M. Pastan I. Gottesman MM. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. *Annual Review of Pharmacology and Toxicology*. 1999 ; 39 : 361-398.
52. Chen CJ. Chin JE. Ueda K. Clark DP. Pastan I. Gottesman MM. Roninson IB. Internal duplication and homology with bacterial transport proteins in the *mdr-1* (P-glycoprotein) gene from multidrug resistant human cells. *Cell*. 1986 ; 47 : 381-389.
53. Higgins CF. and Gottesman MM. (1992) Is the multidrug transporter a flippase? *Trends in Biochemical Sciences*. 17, 18-21.
54. Kast C. Canfield V. Levenson R. and Gros P. (1996) Transmembrane organization of mouse P-glycoprotein determined by epitope insertion and immunofluorescence. *The Journal of Biological Chemistry*. 271: 9240–9248.
55. Martin F. Fromm. The influence of *MDR 1* polymorphisms on P-glycoprotein expression and function in humans. *Advanced Drug Delivery Reviews* 54 (2002) 1295–1310.
56. Robert J. (1999) Multidrug resistance in oncology: diagnostic and

- therapeutic approaches. *European Journal of Clinical Investigation*. 29, 536-45.
57. Verschraagen M. Koks CHW. Schellens JHM. Beijnen JH. P-glycoprotein system as a determinant of drug interactions: The case of digoxin-verapamil. *Pharmacology Research*. 1999 ; 40(4) : 301-306.
58. Watkins PB. The barrier function of CYP3A4 and P-glycoprotein in the small bowel. *Advanced Drug Delivery Reviews*. 1997 ; 27 (8) : 161-170.
59. Fromm MF. P-glycoprotein: A defence mechanism limiting oral bioavailability and CNS accumulation of drugs. *International Journal Clinical Pharmacology and Therapeutics*. 2000 ; 38(2) : 69-74.
60. Tanigawara Y. (2000) Role of P-glycoprotein in drug disposition. *Therapeutic drug monitoring*. 22, 137-40.
61. Shapiro AB. Ling V. Effect of quercetin on Hoechst 33342 transport by purified and reconstituted P-glycoprotein. *Biochemical Pharmacology*. 1997 ; 53 : 587-596.
62. Soldner A. Christians U. Susanto M. Wachter VJ. Silverman JA. Benet LZ. Grapefruit juice activates P-glycoprotein-mediated drug transport. *Pharmaceutical Research*. 1999 ; 16(4) : 478-485.
63. Stouch TR. Gudmundsson O. Progress in understanding the structure–activity relationships of P-glycoprotein. *Advanced Drug Delivery Reviews* 54 (2002) 315–328.
64. Randall W. Yatscoff, Kenneth R. Copeland, Cynthia J. Faraci. Abbott TDx monoclonal antibody assay evaluated for measuring cyclosporine in whole blood. *Clinical Chemistry*. 1990 ; 36(11) :

- 1969-1973.
65. Wang P. Meucci V. Simpson E. Morrison M. Lunetta S. Zajac M. Boeckx R. A monoclonal antibody fluorescent polarization immunoassay for cyclosporine. *Transplantation Proceedings*. 1990 ; 22(3) 1186-1188.
 66. Yamaoka K. Nakagawa T. Uno T. Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. *Journal of Pharmacokinetics and Biopharmaceutics*. 6 : 165-175.
 67. Hsiu SL. Hou YC. Su SF. Wang YH. Tsao CW. and Chao PDL. 2002. Quercetin significantly decreased cyclosporin oral bioavailability in pigs and rats. *Life Sciences*. 72(2002)227-235
 68. 林宣霽，槐花之動力學及其對免疫功能之影響，中國藥學研究所碩士論文，pp. 48-50。
 69. 余鍾萃，芸香 之溶離度改善及其對環孢靈、地高辛動力學之影響，中國藥學研究所碩士論文，pp. 42-46。
 70. Bokkenheuser VD. Shackleton CHL. Winter J. Hydrolysis of dietary flavonoid glycosides by strains of intestinal *Bacteroides* from humans. *The Biochemical Journal*. 1987 ; 248 : 953-956.
 71. Miyake K. Arima H. Hirayama FF. Yamamoto M. Horikawa T. Sumiyoshi H. Noda S. and Uekama K. Improvement of solubility and oral bioavailability of rutin by complexation with 2-Hydroxypropyl- β -cyclodextrin. *Pharmaceutical Development and*

Technology. 2000 ; 5 (3) : 399-407.

72. Fricker G. Drewe J. Huwyler J. Gutmann H. Beglinger C. Relevance of P-glycoprotein for the enteral absorption of cyclosporin A : *in vitro-in vivo* correlation. *British Journal of Pharmacology*. 1996 ; 118 : 1841-1847.
73. Edwards DJ. Fitzsimmons ME. Schuetz EG. Yasuda K. Ducharme MP. Warbasse LH. Woster PM. Schuetz JD. Watkins PB. 6',7'-dihydroxybergamottin in grapefruit juice and Seville orange juice : Effects on ciclosporine disposition, enterocyte CYP3A4 and P-glycoprotein. *Clinical Pharmacology & Therapeutics*. 1999 ; 65 : 237-244.
74. Boumendjel A. Bois F. Beney C. Mariotte AM. Conseil G. and Di Pietro A. B-ring Substituted 5,7-Dihydroxyflavonols with high-affinity binding to P-glycoprotein responsible for cell multidrug resistance. *Bioorganic & Medicinal Chemistry Letters* 11 (2001) 75-77.
75. Boumendjel A. Di Pietro A. Dumontet C. Barron D. Recent advances in the discovery of flavonoids and analogs with high-affinity binding to P-glycoprotein responsible for cancer cell multidrug resistance. *Medicinal Research Reviews*. 22(5):512-29, 2002 Sep.
76. Di Pietro A. Conseil G. Pérez-Victoria J.M. Dayana G. Baubichon-Cortay H. Trompier D. Steinfels E. Jault JM. de Wet H. Maitrejean M. Comte G. Boumendjel A. Mariotte AM. Dumontet C. McIntosh DB. Goffeau A. Castanys S. Gamarro F. and Barron D. Modulation by flavonoids of cell multidrug resistance mediated by

- P-glycoprotein and related ABC transporters. *Cellular and Molecular Life Sciences : CMLS*. 59 (2002) 307–322.
77. de Wet H. McIntosh DB. Conseil G. Baubichon-Cortay H. Krell T. Jault JM. Daskiewicz JB. Barron D. Di Pietro A. Sequence requirements of the ATP-binding site within the C-terminal nucleotide-binding domain of mouse P-glycoprotein: structure-activity relationships for flavonoid binding. *Biochemistry*. 40(34):10382-91, 2001 Aug 28.
78. 蔡玉娟，桑色素之藥物動力學及其對環孢靈吸收之影響，藥物化學研究所碩士論文，pp. 32-61。
79. Shuzhong Z. Morris ME. Effects of the flavonoids biochanin A, morin, phloretin, and silymarin on P-glycoprotein-mediated transport. *The Journal of Pharmacology and Experimental Therapeutics*. Vol.304, No. 3, 1258-1267,2002.
80. Advani R. Fisher GA. Lum BL. A phase I trial of doxorubicin, paclitaxel, and valspodar (PSC 833), a modulator of multidrug resistance. *Clinical Cancer Research : An Official Journal of the American Association for Cancer Research*. 2001;7:1221-1229.
81. Baekelandt M. Lehne G. Trope CG. Phase I/II trial of the multidrug-resistance modulator valspodar combined with cisplatin and doxorubicin in refractory ovarian cancer. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2001;19:2983-2993.
82. Fracasso PM. Brady MF. Moore DH. Phase II study of paclitaxel and valspodar (PSC 833) in refractory ovarian carcinoma: a gynecologic

- oncology group study. *Journal of Clinical oncology: Official Journal of the American Society of Clinical Oncology*. 2001;19:2975-2982.
83. Dorr R. Karanes C. Spier C. Phase I/II study of the P-glycoprotein modulator PSC 833 in patients with acute myeloid leukemia. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*. 2001;19:1589-1599.
84. Chang T. Benet LZ. Hebert MF. The effect of water-soluble vitamin E on cyclosporine pharmacokinetics in healthy volunteers. *Clinical Pharmacology & Therapeutics*. 59(3):297-303, 1996 Mar.
85. Fardel O. Lecureur V. Guillouzo A. The P-glycoprotein multidrug transporter. *General Pharmacology*. 1996 ; 27 : 1283-1291.
86. 何泓璟，槲皮素與桑色素於大白鼠之動力學及其對地高辛動力學之影響，中國藥學研究所碩士論文，pp. 43-45。